| |
[摘要]：The mergers of large pharmaceutical companies, the globalization of R&D processes and the integration of biologics into big pharma have resulted in massive job losses for medicinal chemists in the traditional US pharmaceutical sector. It is not clear and far from guaranteed that such initiatives will result in better, faster or cheaper novel drugs. Given the potential for small molecules to address current medical needs most effectively, it is hoped that the reduction in job opportunities for medicinal chemists in the US is not a reflection of reduced corporate commitment. |
|
